4SC AG provides results for financial year 2023 and outlook for 2024
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
Mit einem Festakt haben Teresa Graham, globale Pharma-Chefin von Roche, Prof. Dr. Hagen Pfundner, Vorstand der Roche Pha…
The Waldburg-Zeil Klinik Bad Wurzach now offers the "gold standard" in gait rehabilitation. This is how the Head of Neur…
The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahea…
Publication in Biotechnology Journal A broadly designed comparative study conducted by researchers from Karolinska Inst…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
ACHEMA 2024 will once again fully integrate the lecture and supporting programme with the exhibition. In 2022, ACHEMA in…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…